Effect of tirzepatide on prediabetics and blood pressure with implications for future research
Author:
Affiliation:
1. Department of Pharmacology , Seth G.S. Medical College and KEM Hospital , Mumbai , India
Publisher
Walter de Gruyter GmbH
Subject
Drug Discovery,Pharmacology,General Medicine,Physiology
Link
https://www.degruyter.com/document/doi/10.1515/jbcpp-2022-0305/pdf
Reference7 articles.
1. Dutta, D, Surana, V, Singla, R, Aggarwal, S, Sharma, M. Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: a cochrane meta-analysis. Indian J Endocrinol Metabol 2021;25:475–83.
2. Jastreboff, AM, Aronne, LJ, Ahmad, NN, Wharton, S, Connery, L, Alves, B, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387:205–16. https://doi.org/10.1056/NEJMoa2206038.
3. Willard, FS, Douros, JD, Gabe, MB, Showalter, AD, Wainscott, DB, Suter, TM, et al.. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight 2020;5:e140532. https://doi.org/10.1172/jci.insight.140532.
4. Elsayed, NA, Aleppo, G, Aroda, VR, Bannuru, RR, Brown, FM, Bruemmer, D, et al.. Pharmacologic approaches to glycemic treatment: standards of care in diabetes—2023. Diabetes Care 2023;46:S140–57.
5. Shi, M, Zhang, X, Wang, H. The prevalence of diabetes, prediabetes and associated risk factors in Hangzhou, Zhejiang province: a community-based cross-sectional study. Diabetes Metab Syndr Obes Targets Ther 2022;15:713–21.
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3